drugset / Trial / NCT02384070

Simplified Anti-Thrombotic Therapy for FFR

NCT02384070

Completed 300 enrolled Odessa Heart Institute
RandomizedParallel-groupTriple-blindDiagnostic

Summary

Despite the routine use of procedural anti-coagulation and anti-platelet therapy for FFR calculation, no study has evaluated the optimal anti-thrombotic regimen in patients undergoing FFR. Therefore, the aim of the Evaluation of Simplified Anti-Thrombotic Therapy for Coronary Fractional Flow Reserve (SMART-FFR) study was to evaluate the safety of using a simplified anti-thrombotic regimen with only upstream dual anti-platelet therapy (DAT) with aspirin and clopidogrel, compared with anticoagulation plus single- or- DAT therapy in patients with intermediate coronary artery stenosis undergoing FFR calculation during elective coronary angiography.

Timeline

Start
2009-01
Primary completion
2013-12
Completion
2014-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Aspirin Small molecule 325 mg
Subject Bivalirudin Peptide 1.75 mg/kg Intravenous
Subject Clopidogrel Small molecule 600 mg